Roche To Make Further In-Roads With Evrysdi In Newborn And Older SMA Patients
50% Of Older US Patients Untreated
Executive Summary
Roche’s Evrysdi is set to expand its license into pre-symptomatic children this year but the company is also focused on how to get greater numbers of older patients to seek treatment.
You may also be interested in...
It Takes A Village: Roche’s India Rare Disease Approach, Crowdfunding Support
Roche Pharma India CEO and managing director, V Simpson Emmanuel, outlines the company's multi-forked approach, including collaborating with a crowdfunding platform, to move the access and treatment needle for Evrysdi in India. The Swiss firm, along with industry associations, also suggests the need for a formal accelerated regulatory pathway in India for rare diseases.
Allogene May Have Cracked The Off-The-Shelf CAR-T Problem
Allogeneic candidate’s durability is holding up thanks to a novel conditioning regimen, but Phase II data will be crucial test.
Antibody-Drug Conjugates Take Their Place On The ASCO 2023 Stage
Investment from big and small players against existing and novel targets is making antibody-drug conjugates one of the fastest-growing fields in oncology, as attested by their presence at the upcoming ASCO meeting.